ES2367480T3 - Administración de agentes para el tratamiento de inflamación. - Google Patents

Administración de agentes para el tratamiento de inflamación. Download PDF

Info

Publication number: ES2367480T3
Authority: ES; Spain
Prior art keywords: alpha; integrin; agents; natalizumab; patients
Prior art date: 2002-02-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES03709277T

Other languages

English (en)

Spanish (es)

Inventor

Julie Taylor

Ted A. Yednock

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Elan Pharmaceuticals LLC

Original Assignee

Elan Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-25

Filing date

2003-02-25

Publication date

2011-11-03

2003-02-25 Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC

2011-11-03 Application granted granted Critical

2011-11-03 Publication of ES2367480T3 publication Critical patent/ES2367480T3/es

2023-02-25 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

206010061218 Inflammation Diseases 0.000 title claims abstract description 45
230000004054 inflammatory process Effects 0.000 title claims abstract description 45
238000011282 treatment Methods 0.000 title description 65
239000003795 chemical substances by application Substances 0.000 claims abstract description 105
201000006417 multiple sclerosis Diseases 0.000 claims abstract description 70
229960005027 natalizumab Drugs 0.000 claims abstract description 69
108010041012 Integrin alpha4 Proteins 0.000 claims abstract description 38
230000001575 pathological effect Effects 0.000 claims abstract description 31
230000001684 chronic effect Effects 0.000 claims abstract description 30
239000000539 dimer Substances 0.000 claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
239000012634 fragment Substances 0.000 claims abstract description 12
101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 claims description 34
102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 claims description 34
230000003902 lesion Effects 0.000 description 38
239000000203 mixture Substances 0.000 description 37
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
239000002671 adjuvant Substances 0.000 description 35
239000000902 placebo Substances 0.000 description 34
229940068196 placebo Drugs 0.000 description 34
230000000694 effects Effects 0.000 description 32
201000010099 disease Diseases 0.000 description 28
102000005962 receptors Human genes 0.000 description 25
108020003175 receptors Proteins 0.000 description 25
238000000034 method Methods 0.000 description 23
102000006495 integrins Human genes 0.000 description 22
108010044426 integrins Proteins 0.000 description 22
238000009472 formulation Methods 0.000 description 21
238000002595 magnetic resonance imaging Methods 0.000 description 19
239000003814 drug Substances 0.000 description 17
150000001875 compounds Chemical class 0.000 description 15
208000024891 symptom Diseases 0.000 description 15
208000011231 Crohn disease Diseases 0.000 description 14
210000002966 serum Anatomy 0.000 description 13
230000001225 therapeutic effect Effects 0.000 description 13
230000002411 adverse Effects 0.000 description 12
230000027455 binding Effects 0.000 description 12
229940079593 drug Drugs 0.000 description 12
230000001629 suppression Effects 0.000 description 12
208000022559 Inflammatory bowel disease Diseases 0.000 description 11
210000000265 leukocyte Anatomy 0.000 description 11
239000000243 solution Substances 0.000 description 11
108010008212 Integrin alpha4beta1 Proteins 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
230000028993 immune response Effects 0.000 description 10
238000001802 infusion Methods 0.000 description 10
230000000750 progressive effect Effects 0.000 description 10
230000009467 reduction Effects 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 9
239000000523 sample Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
230000001154 acute effect Effects 0.000 description 8
238000013270 controlled release Methods 0.000 description 8
-1 for example Proteins 0.000 description 8
229960000485 methotrexate Drugs 0.000 description 8
230000003389 potentiating effect Effects 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
239000011534 wash buffer Substances 0.000 description 8
108010005716 Interferon beta-1a Proteins 0.000 description 7
108010050904 Interferons Proteins 0.000 description 7
102000014150 Interferons Human genes 0.000 description 7
239000013543 active substance Substances 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
239000003246 corticosteroid Substances 0.000 description 7
229960001334 corticosteroids Drugs 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
239000003623 enhancer Substances 0.000 description 7
239000003862 glucocorticoid Substances 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 7
150000003431 steroids Chemical class 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
206010051290 Central nervous system lesion Diseases 0.000 description 6
206010009900 Colitis ulcerative Diseases 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
201000006704 Ulcerative Colitis Diseases 0.000 description 6
229940037003 alum Drugs 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
229960004461 interferon beta-1a Drugs 0.000 description 6
229940047124 interferons Drugs 0.000 description 6
210000004698 lymphocyte Anatomy 0.000 description 6
229960004618 prednisone Drugs 0.000 description 6
230000004044 response Effects 0.000 description 6
229940037128 systemic glucocorticoids Drugs 0.000 description 6
238000012360 testing method Methods 0.000 description 6
238000011269 treatment regimen Methods 0.000 description 6
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
239000002775 capsule Substances 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
239000007943 implant Substances 0.000 description 5
229960000598 infliximab Drugs 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
229960004584 methylprednisolone Drugs 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 5
239000000829 suppository Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
230000036642 wellbeing Effects 0.000 description 5
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 4
102400000739 Corticotropin Human genes 0.000 description 4
101800000414 Corticotropin Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
208000016192 Demyelinating disease Diseases 0.000 description 4
108010072051 Glatiramer Acetate Proteins 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
102100032818 Integrin alpha-4 Human genes 0.000 description 4
108010005714 Interferon beta-1b Proteins 0.000 description 4
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
229940121363 anti-inflammatory agent Drugs 0.000 description 4
239000002260 anti-inflammatory agent Substances 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
239000000812 cholinergic antagonist Substances 0.000 description 4
208000037976 chronic inflammation Diseases 0.000 description 4
230000006020 chronic inflammation Effects 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
229960000258 corticotropin Drugs 0.000 description 4
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
230000001186 cumulative effect Effects 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
210000003989 endothelium vascular Anatomy 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
229960003161 interferon beta-1b Drugs 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000007774 longterm Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
210000000440 neutrophil Anatomy 0.000 description 4
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
230000002085 persistent effect Effects 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000000306 recurrent effect Effects 0.000 description 4
229940031439 squalene Drugs 0.000 description 4
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000009120 supportive therapy Methods 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
238000011277 treatment modality Methods 0.000 description 4
YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 3
108010039939 Cell Wall Skeleton Proteins 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
108010036949 Cyclosporine Proteins 0.000 description 3
206010012305 Demyelination Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
241000792859 Enema Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
102100025390 Integrin beta-2 Human genes 0.000 description 3
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
108090000467 Interferon-beta Proteins 0.000 description 3
102000003996 Interferon-beta Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000005018 casein Substances 0.000 description 3
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
235000021240 caseins Nutrition 0.000 description 3
210000004520 cell wall skeleton Anatomy 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000007920 enema Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
239000000834 fixative Substances 0.000 description 3
229940042385 glatiramer Drugs 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
230000003308 immunostimulating effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
229960001388 interferon-beta Drugs 0.000 description 3
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
229960000991 ketoprofen Drugs 0.000 description 3
239000000463 material Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229960001428 mercaptopurine Drugs 0.000 description 3
238000013508 migration Methods 0.000 description 3
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
229960001156 mitoxantrone Drugs 0.000 description 3
229940035032 monophosphoryl lipid a Drugs 0.000 description 3
229960002009 naproxen Drugs 0.000 description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
229960005489 paracetamol Drugs 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229960003073 pirfenidone Drugs 0.000 description 3
ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
229940122414 Alpha4 integrin antagonist Drugs 0.000 description 2
241000272478 Aquila Species 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
229940124638 COX inhibitor Drugs 0.000 description 2
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
229920002971 Heparan sulfate Polymers 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
206010022004 Influenza like illness Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
108090000184 Selectins Proteins 0.000 description 2
102000003800 Selectins Human genes 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
238000010171 animal model Methods 0.000 description 2
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
229940125714 antidiarrheal agent Drugs 0.000 description 2
239000003793 antidiarrheal agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
229960002170 azathioprine Drugs 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
208000029028 brain injury Diseases 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000020411 cell activation Effects 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
229940111134 coxibs Drugs 0.000 description 2
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000003210 demyelinating effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
229940095399 enema Drugs 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
238000013265 extended release Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
108010021315 integrin beta7 Proteins 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229960004963 mesalazine Drugs 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
229960005225 mifamurtide Drugs 0.000 description 2
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
229960000761 pemoline Drugs 0.000 description 2
230000035515 penetration Effects 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000001397 quillaja saponaria molina bark Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
229930182490 saponin Natural products 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229960001940 sulfasalazine Drugs 0.000 description 2
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical class N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
241001106067 Atropa Species 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010048610 Cardiotoxicity Diseases 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
229920002284 Cellulose triacetate Polymers 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
241000759568 Corixa Species 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
208000003164 Diplopia Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019027 Haemothorax Diseases 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010022095 Injection Site reaction Diseases 0.000 description 1
108010022222 Integrin beta1 Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
229920000288 Keratan sulfate Polymers 0.000 description 1
108010092694 L-Selectin Proteins 0.000 description 1
102100033467 L-selectin Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
206010025280 Lymphocytosis Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
241001092142 Molina Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
CKMOQBVBEGCJGW-LLIZZRELSA-L OC1=CC=C(C=C1C(=O)O[Na])\N=N\C1=CC=C(C=C1)C(=O)NCCC(=O)O[Na] Chemical compound OC1=CC=C(C=C1C(=O)O[Na])\N=N\C1=CC=C(C=C1)C(=O)NCCC(=O)O[Na] CKMOQBVBEGCJGW-LLIZZRELSA-L 0.000 description 1
208000003435 Optic Neuritis Diseases 0.000 description 1
108010035766 P-Selectin Proteins 0.000 description 1
102100023472 P-selectin Human genes 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
238000001358 Pearson's chi-squared test Methods 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037714 Quadriplegia Diseases 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
206010040026 Sensory disturbance Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical class [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
229930003779 Vitamin B12 Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
BOIZHGCLUSQNLD-UHFFFAOYSA-N acetic acid;1h-indole Chemical class CC(O)=O.C1=CC=C2NC=CC2=C1 BOIZHGCLUSQNLD-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000001243 acetic acids Chemical class 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
229960001280 amantadine hydrochloride Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000003501 anti-edematous effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229940064856 azulfidine Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
229950000210 beclometasone dipropionate Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
208000025698 brain inflammatory disease Diseases 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
231100000259 cardiotoxicity Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
208000013507 chronic prostatitis Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
GKEGFOKQMZHVOW-KUTGSRRKSA-M clidinium bromide Chemical compound [Br-].C1([C@H]2CC[N@+](CC2)(C1)C)OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 GKEGFOKQMZHVOW-KUTGSRRKSA-M 0.000 description 1
229960005098 clidinium bromide Drugs 0.000 description 1
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
229960003120 clonazepam Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000013068 control sample Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
229960003572 cyclobenzaprine Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
229940019765 dermatin Drugs 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
229960002777 dicycloverine Drugs 0.000 description 1
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
229960004192 diphenoxylate Drugs 0.000 description 1
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
229960002011 fludrocortisone Drugs 0.000 description 1
AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
239000012530 fluid Substances 0.000 description 1
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
229940014144 folate Drugs 0.000 description 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
150000002241 furanones Chemical class 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960003776 glatiramer acetate Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000005931 immune cell recruitment Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229960003284 iron Drugs 0.000 description 1
230000001788 irregular Effects 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
229960001571 loperamide Drugs 0.000 description 1
RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960003803 meclofenamic acid Drugs 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960003464 mefenamic acid Drugs 0.000 description 1
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
229960001929 meloxicam Drugs 0.000 description 1
KBOPZPXVLCULAV-UHFFFAOYSA-M mesalaminate(1-) Chemical compound NC1=CC=C(O)C(C([O-])=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-M 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
229960005249 misoprostol Drugs 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229940063121 neoral Drugs 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
230000007971 neurological deficit Effects 0.000 description 1
208000015015 neurological dysfunction Diseases 0.000 description 1
229960000965 nimesulide Drugs 0.000 description 1
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
229960004110 olsalazine Drugs 0.000 description 1
229940124624 oral corticosteroid Drugs 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
108010049224 perlecan Proteins 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
WVKSUFYQOHQCMM-YGZHYJPASA-N prednisolone sulfobenzoate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)C1=CC=CC(S(O)(=O)=O)=C1 WVKSUFYQOHQCMM-YGZHYJPASA-N 0.000 description 1
229950004954 prednisolone sulfobenzoate Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
229960002393 primidone Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
239000001294 propane Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
150000003217 pyrazoles Chemical class 0.000 description 1
229940038850 rebif Drugs 0.000 description 1
230000001739 rebound effect Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
231100000279 safety data Toxicity 0.000 description 1
229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
150000003872 salicylic acid derivatives Chemical class 0.000 description 1
229960000953 salsalate Drugs 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
239000000565 sealant Substances 0.000 description 1
201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
229960002211 sulfapyridine Drugs 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
KYLIMUJRJDIPPF-UHFFFAOYSA-N trisalicylate Chemical compound O=C1OC2=CC=CC=C2C(=O)OC2=CC=CC=C2C(=O)OC2=CC=CC=C12 KYLIMUJRJDIPPF-UHFFFAOYSA-N 0.000 description 1
150000003648 triterpenes Chemical class 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
235000019163 vitamin B12 Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ES03709277T 2002-02-25 2003-02-25 Administración de agentes para el tratamiento de inflamación. Expired - Lifetime ES2367480T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US36013402P	2002-02-25	2002-02-25
US360134P		2002-02-25
US374501P		2002-04-23

Publications (1)

Publication Number	Publication Date
ES2367480T3 true ES2367480T3 (es)	2011-11-03

Family

ID=44800361

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES03709277T Expired - Lifetime ES2367480T3 (es)	2002-02-25	2003-02-25	Administración de agentes para el tratamiento de inflamación.

Country Status (2)

Country	Link
ES (1)	ES2367480T3 (ru)
UA (1)	UA85537C2 (ru)

2003
- 2003-02-25 UA UA20040907793A patent/UA85537C2/ru unknown
- 2003-02-25 ES ES03709277T patent/ES2367480T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
UA85537C2 (ru)	2009-02-10

Publication	Publication Date	Title
ES2531852T3 (es)	2015-03-20	Administración de agentes para el tratamiento de la inflamación
US12460012B2 (en)	2025-11-04	Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
KR20240162603A (ko)	2024-11-15	발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
ES2367480T3 (es)	2011-11-03	Administración de agentes para el tratamiento de inflamación.
HK1073997B (en)	2012-03-30	Administration of agents for the treatment of inflammation
AU2012202155B2 (en)	2014-08-21	Administration of agents for the treatment of inflammation
AU2014265076B2 (en)	2016-09-01	Administration of agents for the treatment of inflammation
Fernández et al.	2014	Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)(III)
HK1161278A (en)	2012-08-24	Administration of agents for the treatment of inflammation
HK1159138A (en)	2012-07-27	Administration of agents for the treatment of inflammation
HK1149773A (en)	2011-10-14	Administration of agents for the treatment of inflammation